IND Granted to Triphendiol
The United States Food and Drug Administration has granted Marshall Edwards, Inc. an investigative new drug (IND) indication for triphendiol (NV-196).
Triphendiol is a chemosensitizing agent that is thought to depolarize mitochrondria and downregulate XIAP. It has also demonstrated broad cytostatic and cytotoxic properties against human cancer cells in vitro.
The IND indication is for triphendiol to be used in combination with Gemzar® (gemcitabine) for the treatment of unresectable, locally advanced, or metastatic pancreatic and bile duct cancers. The IND will enable a Phase IB study of triphendiol to proceed.
Zenocutuzumab - the first approved systemic therapy for patients with NRG1 fusion–positive NSCLC or pancreatic adenocarcinoma.
Zenocutuzumab targeted therapy approved for treatment of pancreatic ductal adenocarcinoma and non-small cell lung cancer with NRG1 fusions.
Immunotherapy After Chemoradiotherapy Promising in Limited-Stage Small Cell Lung Cancer
Adjuvant therapy with Imfinzi (durvalumab) significantly improved survival outcomes for patients with limited-stage SCLC
Breakthrough in Understanding Tamoxifen's Effectiveness in Breast Cancer: Gut Bacteria Play a Crucial Role
Since tamoxifen is taken orally and travels through the digestive system, variations in patient responses may be connected to the gut microbiome—the trillions of bacteria in our intestines that differ significantly from one person to another.
